The kidney tests that belong in a heart-health conversation: eGFR and urine ACR
About this article: AI-assisted, not independently clinically reviewed
Prepared with AI-assisted research using the sources below. Not independently reviewed by a clinician. Guidance and individual circumstances can change; use this article to prepare for a clinical conversation, not to choose treatment.
Sources checked 2026-09-05. Last updated 2026-09-05.
The short version
- eGFR and urine ACR answer different questions and are often needed together.
- One abnormal result does not automatically establish chronic kidney disease.
- A sudden deterioration can need prompt care; do not wait three months to seek advice.
Heart-health records often contain cholesterol and blood-pressure results but omit the urine test that helps assess kidney risk. Kidney health is not captured by a single creatinine value. Understanding which tests you have, and which you do not, can make the next appointment more useful.
Two tests, two kinds of information
The estimated glomerular filtration rate, or eGFR, estimates how well the kidneys filter blood. It is commonly calculated using blood creatinine. Urine albumin-to-creatinine ratio, written ACR or UACR, looks for albumin leakage in relation to urine creatinine. The urine creatinine in this ratio is not interchangeable with the blood creatinine used to estimate filtration.
Early kidney disease often produces no symptoms. NIDDK highlights diabetes, high blood pressure, heart disease and a family history of kidney failure as reasons to discuss testing. Ask about both blood and urine results rather than assuming that a normal-looking blood panel has answered every kidney question.
Chronic means persistent, not one unexpected number
KDIGO defines chronic kidney disease using abnormalities present for at least three months. These include persistently reduced eGFR below 60 mL/min/1.73 m² or markers of kidney damage, such as ACR at least 30 mg/g, approximately 3 mg/mmol. An eGFR of 60 or above does not exclude CKD if persistent markers of damage are present. Equally, an eGFR between 60 and 89 alone does not establish CKD.
Evidence: KDIGO 2024: CKD evaluation and management guideline
An unexpected result may need an earlier repeat and investigation. The three-month definition is not permission to wait if kidney function has suddenly worsened or someone is unwell. Creatinine-based estimates also have limitations, including effects of muscle mass; a clinician may use additional information or cystatin C when a more accurate estimate is important.
Evidence: KDIGO 2024: CKD evaluation and management guideline
Why this belongs beside your cardiovascular results
KDIGO assesses risk using the combination of filtration and albuminuria, not just one stage label. Kidney findings can influence cardiovascular prevention, medication choices and monitoring. The 2024 guideline remains the current global guideline on KDIGO's website; a focused treatment update is underway. An announced update is not the same as a completed new recommendation.
Evidence: KDIGO 2024: CKD evaluation and management guideline · KDIGO: current guideline and focused-update status
What a major treatment trial showed
EMPA-KIDNEY randomised 6,609 people with chronic kidney disease at risk of progression to empagliflozin or placebo. Over a median two years, kidney disease progression or cardiovascular death occurred in 13.1% versus 16.9%. Results were consistent in participants with and without diabetes. This helps explain why a medicine associated with diabetes may be discussed in kidney care even when someone does not have diabetes.
Evidence: EMPA-KIDNEY Collaborative Group, NEJM 2022/2023: empagliflozin in CKD
The primary outcome combined several events. Its improvement does not prove that every individual component improved, and the trial did not find a significant difference in every cardiovascular endpoint. It also does not mean everybody with one mildly abnormal test should start the medicine. Eligibility, side effects and monitoring require individual assessment.
Evidence: EMPA-KIDNEY Collaborative Group, NEJM 2022/2023: empagliflozin in CKD
Keep a record that preserves the meaning
- Save the eGFR, blood creatinine and urine ACR as separate named tests, with dates and original units.
- Keep previous results so a clinician can see the trend and determine whether a change is persistent.
- Note illness, dehydration or medication changes around the test, without deciding on your own that they explain it.
- Ask whether a urine sample needs repeating and when. Keep the requested follow-up date visible.
- If a scan or OCR tool copied the report, check the decimal point, unit and test name against the original before sharing it.
Useful questions are: 'Do these results show a persistent problem? What is my risk when the two tests are considered together? Does the result change my treatment or monitoring?' The purpose of tracking is to support those decisions, not to label yourself from a colour-coded result.
This article is educational and is not medical advice, a diagnosis, or a treatment recommendation. CardioTrack is not intended for diagnosis or treatment. Always discuss your own results with a qualified clinician.